• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Cytokinetics (CYTK) Undervalued On New Aficamten Data?

    Simply Wall St·11/12/2026 03:31:20
    Listen to the news

    Cytokinetics (CYTK) is back in focus after new aficamten data presented at the Hypertrophic Cardiomyopathy Medical Society and American Heart Association Scientific Sessions highlighted cardiac remodeling, biomarker changes, and quality-of-life outcomes in patients with hypertrophic cardiomyopathy.

    Cytokinetics has been volatile, with the share price rising 4.18% in the last day and 5.36% over the week to US$58.53, yet still down 21.04% over three months. The three year total shareholder return of 84.75% contrasts with a weaker 1 year total shareholder return of 10.67%. This hints at strong longer term enthusiasm tempered by recent reassessment of risk as new trial data and earnings land.

    Scan more cardiology focused opportunities by lining up Cytokinetics against 37 healthcare AI stocks that could also be moving on breakthrough data and real-world treatment potential.

    The sharp three month pullback, set against a still strong three year return, leaves Cytokinetics looking like either a business catching up with its science or a sentiment swing around familiar biotech risks. So what does the current valuation actually reflect?

    Most Popular Narrative: 46% Undervalued

    Cytokinetics last closed at $58.53, while the analyst consensus Narrative on Simply Wall St anchors fair value at $107.80 using a 7.33% discount rate and detailed earnings and revenue forecasts. That framework leans heavily on how its heart drugs could scale over time.

    The rising incidence of cardiovascular and neuromuscular diseases, driven by an aging global population, is expanding the addressable market for Cytokinetics'' therapies; ongoing late-stage trials and anticipated approvals in multiple geographies position the company to capture increased demand and drive significant future revenue growth.

    See why 10 investors see Cytokinetics as 46% undervalued.

    The same Narrative ties that demand story into explicit numbers. It works off analyst models that point to revenue of $1.0b and earnings of $178.9m by 2029, alongside a future P/E of about 104x on those projected earnings and a discount rate of 7.33% to translate those expectations into today’s fair value.

    Readers should weigh that $107.80 fair value, which is a very large premium to the current $58.53 share price, against the clear risks in the cardiomyopathy pipeline, the current loss of $777.9m, negative equity, and the expectation that profitability is still a few years away according to those same forecasts.

    Result: Fair Value of $107.80 (UNDERVALUED)

    Still, the Cytokinetics story can break if aficamten or Myqorzo run into regulatory or uptake hurdles, or if high expenses continue to widen reported losses.

    Find out about the key risks to this Cytokinetics narrative.

    Next Steps

    If this mix of enthusiasm and caution around Cytokinetics feels conflicting, that is the point. It is exactly why acting now to test the numbers, weigh the trade offs, and see how the story lands for you personally starts with understanding the balance of 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond Cytokinetics?

    Do not stop your research with Cytokinetics. The market rarely rewards tunnel vision, and you risk missing compelling setups that better match your style and risk tolerance.